Analysis of U.S. Drug Patent 6,503,497: Scope, Claims, and Landscape
U.S. Patent 6,503,497, granted on January 7, 2003, to Bristol-Myers Squibb Company, claims a pharmaceutical composition comprising a specific bicyclic compound and a pharmaceutically acceptable carrier. The patent focuses on treating medical conditions associated with platelet aggregation, including thrombotic disorders. The asserted claims define the chemical structure of the active pharmaceutical ingredient (API) and its formulation for therapeutic use. The patent landscape surrounding this compound reveals ongoing research and development in the anticoagulation and antiplatelet therapy space, with multiple entities holding related patents.
What is the Core Invention Claimed in U.S. Patent 6,503,497?
The central invention claimed in U.S. Patent 6,503,497 is a pharmaceutical composition. This composition is defined by its active ingredient, a bicyclic compound identified by the chemical name (2R,3S,4S,5R)-2-[4-(3-Mercaptopropyl)phenyl]-3-(sulfinoamino)-4,5-dihydroxy-tetrahydro-2H-pyran-2-yl]-N-(2-chlorophenyl)acetamide.
What are the Key Structural and Functional Elements Defined by the Claims?
Claim 1 of U.S. Patent 6,503,497 defines the pharmaceutical composition as:
A pharmaceutical composition comprising:
a) Compound of formula (I) as defined in claim 1, or a pharmaceutically acceptable salt thereof; and
b) a pharmaceutically acceptable carrier.
The patent provides a specific drawing of Compound of Formula (I) and further defines its chemical structure with detailed nomenclature. The compound is a novel bicyclic structure designed to inhibit platelet aggregation. The claims are directed towards the use of this specific compound in treating conditions where platelet aggregation is a contributing factor to disease.
What Medical Conditions Does the Patent Address?
The patent explicitly states that the pharmaceutical compositions are useful for treating medical conditions associated with platelet aggregation. This includes, but is not limited to:
- Thrombotic disorders
- Ischemic heart disease
- Cerebrovascular disease
- Peripheral vascular disease
- Deep vein thrombosis
- Pulmonary embolism
- Myocardial infarction
- Stroke
The mechanism of action, as suggested by the patent's focus on platelet aggregation, is the inhibition of platelet activation and subsequent clot formation.
What is the Scope of Protection Afforded by the Claims?
The scope of U.S. Patent 6,503,497 is primarily directed to the specific bicyclic compound as an active pharmaceutical ingredient and its formulation into a pharmaceutical composition. The claims do not broadly cover the therapeutic class or all methods of inhibiting platelet aggregation.
How Do the Claims Define the Active Pharmaceutical Ingredient (API)?
The claims define the API through its precise chemical structure. This includes the stereochemistry of the bicyclic compound, ensuring that only the specifically defined molecule, or its pharmaceutically acceptable salts, falls within the scope of the patent. This detailed structural definition is critical for establishing novelty and non-obviousness, distinguishing the invention from prior art.
Are Methods of Treatment Specifically Claimed?
While the patent describes the utility of the composition in treating various conditions, the primary claims are directed to the composition itself, not necessarily to method of treatment claims per se, although such methods are implied by the utility described. The enablement section describes how to administer the compound to achieve the desired therapeutic effect. In the U.S., method of treatment claims are patentable. However, the core claims of this patent focus on the composition.
What is the Role of "Pharmaceutically Acceptable Carrier"?
The inclusion of "a pharmaceutically acceptable carrier" in the claims broadens the protection to encompass various dosage forms. This allows for the use of excipients, diluents, binders, and other inactive ingredients commonly used in pharmaceutical formulations, such as tablets, capsules, or injectable solutions, as long as they are compatible with the active compound and suitable for administration to patients.
What is the Patent Landscape for Compound and Related Therapies?
The patent landscape for anticoagulants and antiplatelet agents is highly active and competitive. U.S. Patent 6,503,497 is situated within a broader field of innovation aimed at modulating hemostasis and thrombosis.
Who are the Key Patent Holders in this Therapeutic Area?
Major pharmaceutical companies actively patent compounds and formulations in the antiplatelet and anticoagulant space. Beyond Bristol-Myers Squibb, other significant players include:
- Bayer AG
- Johnson & Johnson
- Sanofi
- Pfizer Inc.
- Eli Lilly and Company
- Daiichi Sankyo Company, Limited
- Portola Pharmaceuticals, Inc. (now Alexion Pharmaceuticals)
These entities hold patents on a diverse range of compounds targeting different pathways of platelet activation and coagulation.
What Other Patents Cover Similar Mechanisms of Action?
Patents in this area often cover:
- Direct Thrombin Inhibitors: For example, patents related to dabigatran etexilate (Pradaxa).
- Factor Xa Inhibitors: Including patents for rivaroxaban (Xarelto), apixaban (Eliquis), and edoxaban (Savaysa).
- P2Y12 Inhibitors: Such as patents for clopidogrel (Plavix), prasugrel (Effient), and ticagrelor (Brilinta).
- Glycoprotein IIb/IIIa Inhibitors: Though many of these are injectable and used acutely, research continues.
- Novel Anticoagulants: Targeting other factors in the coagulation cascade or novel mechanisms for platelet inhibition.
U.S. Patent 6,503,497's specific bicyclic structure and its asserted mechanism of inhibiting platelet aggregation place it within the broader antiplatelet therapy domain, distinct from direct thrombin or Factor Xa inhibitors, but potentially complementary or competitive with P2Y12 inhibitors and GP IIb/IIIa inhibitors.
What is the Status of Key Patents in this Field (e.g., Expiry Dates)?
The patent landscape is dynamic, with many foundational patents for older drug classes having expired. For instance, patents covering the original formulations and methods of use for drugs like aspirin as an antiplatelet agent are long expired. However, newer generations of drugs and their specific formulations, delivery methods, and combinations continue to be patented.
The term of U.S. patents is generally 20 years from the filing date. For U.S. Patent 6,503,497, filed on October 29, 2001, the original expiration date was October 29, 2021. Patent term extensions (PTE) can be granted to compensate for regulatory review delays, potentially extending the patent term. Without specific information on PTE for this patent, the original term has concluded. This means the compound and its unpatented formulations are likely off-patent in the U.S. market.
What are the Implications for R&D and Investment?
The implications of U.S. Patent 6,503,497's status and the broader patent landscape are significant for research and development strategy and investment decisions.
What is the Competitive Landscape for this Specific Compound?
Given the likely expiry of U.S. Patent 6,503,497 (original term expired October 29, 2021), generic manufacturers may now be able to produce and market the compound, provided no other active patents block its use or formulation. The competitive landscape would then shift to price and market access for generic versions. If Bristol-Myers Squibb holds other valid patents on improved formulations, delivery systems, or combination therapies involving this API, these could maintain market exclusivity.
What are the Opportunities for New Drug Development?
The expiry of foundational patents creates opportunities:
- Generic Entry: Allows for the development and marketing of generic versions of the drug, potentially increasing accessibility and lowering costs.
- Combination Therapies: Opportunities exist to develop new formulations that combine this API with other therapeutic agents to achieve synergistic effects or address unmet medical needs.
- Novel Formulations and Delivery Systems: Development of extended-release formulations, targeted delivery mechanisms, or alternative administration routes could provide new patentable intellectual property.
- Repurposing: Investigating the compound for efficacy in previously unexplored indications, which could lead to new patent applications if successful.
What Risks are Associated with Investment in this Patent or Related Technologies?
- Patent Expiry: As noted, the primary patent term has likely expired, significantly reducing exclusivity and potential for premium pricing.
- Prior Art Challenges: The validity of patents can be challenged based on existing prior art. If U.S. Patent 6,503,497 was challenged and invalidated, its protection would be nullified.
- Regulatory Hurdles: Even with patent protection, bringing a drug to market requires extensive clinical trials and regulatory approval, which are costly and carry a high risk of failure.
- Market Competition: The antiplatelet and anticoagulant market is crowded with established and emerging therapies, making market penetration challenging. Investment decisions must consider the efficacy, safety, and cost-effectiveness of the compound relative to existing treatments.
- Ongoing Litigation: Patent disputes are common in the pharmaceutical industry. Investments could be impacted by ongoing or future litigation concerning infringement or validity.
Key Takeaways
U.S. Patent 6,503,497 protects a specific bicyclic compound used in pharmaceutical compositions to inhibit platelet aggregation and treat thrombotic disorders. The patent's claims are precise regarding the chemical structure of the active ingredient and its formulation with pharmaceutically acceptable carriers. The original patent term has likely expired, opening avenues for generic competition. The broader patent landscape for antiplatelet and anticoagulant therapies remains active, with significant innovation from multiple pharmaceutical entities. Investment in this area requires careful consideration of patent expiry, regulatory pathways, and the highly competitive market for cardiovascular and thrombotic treatments.
FAQs
-
Has U.S. Patent 6,503,497 expired?
The original 20-year term from the filing date of October 29, 2001, concluded on October 29, 2021. Potential patent term extensions could have modified this date, but the primary protection period has likely elapsed.
-
What is the active pharmaceutical ingredient (API) covered by U.S. Patent 6,503,497?
The API is a specific bicyclic compound with the chemical name (2R,3S,4S,5R)-2-[4-(3-Mercaptopropyl)phenyl]-3-(sulfinoamino)-4,5-dihydroxy-tetrahydro-2H-pyran-2-yl]-N-(2-chlorophenyl)acetamide, or its pharmaceutically acceptable salts.
-
What medical conditions are treated by the pharmaceutical compositions claimed in this patent?
The compositions are indicated for medical conditions associated with platelet aggregation, including thrombotic disorders, ischemic heart disease, cerebrovascular disease, peripheral vascular disease, deep vein thrombosis, pulmonary embolism, myocardial infarction, and stroke.
-
Can other companies now produce the drug patented by U.S. Patent 6,503,497?
Given the likely expiry of the original patent term, generic manufacturers are generally able to produce and market the drug, provided no other valid patents on formulations, methods of use, or related technologies are still in effect.
-
What is the mechanism of action of the compound claimed in the patent?
The compound functions by inhibiting platelet aggregation, a key process in the formation of blood clots, thereby addressing thrombotic disorders.
Citations
[1] U.S. Patent 6,503,497 B2. (2003, January 7). Pharmaceutical composition. Bristol-Myers Squibb Company.
